Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 23, 2023
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
[ Mon, Jan 23rd 2023
] - WOPRAI
Mani Foroohar Maintained (BEAM) at Buy with Decreased Target to $77 on, Jan 23rd, 2023
Mani Foroohar of SVB Leerink, Maintained "Beam Therapeutics Inc." (BEAM) at Buy with Decreased Target from $81 to $77 on, Jan 23rd, 2023.
Mani has made no other calls on BEAM in the last 4 months.
There are 3 other peers that have a rating on BEAM. Out of the 3 peers that are also analyzing BEAM, 1 agrees with Mani's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Maintained at Hold with Decreased Target to $53 on, Tuesday, November 8th, 2022
These are the ratings of the 2 analyists that currently disagree with Mani
- Kostas Biliouris of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $66 on, Tuesday, December 20th, 2022
- Samantha Semenkow of "Citigroup" Initiated at Strong Buy and Held Target at $62 on, Tuesday, December 13th, 2022
